METASTATIC PROSTATE CANCER

This study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is an antibody designed to guide the body's immune cells to attack cancer cells. The trial has two parts: firs…

This early-phase study tests whether combining a targeted radiation drug (177Lu-PSMA-617) with liver-directed therapy is safe for men with metastatic castration-resistant prostate cancer that has spread to the liver. About 30 participants will receive the combination to check for…

This study tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug aims to find and destroy cancer cells with radiation. Researchers will check safety and tu…

This study for veterans with prostate cancer that has returned in a few spots (1-10) tests whether adding PET-directed local therapy to standard hormone therapy can delay the cancer from becoming resistant to treatment. About 464 participants will be randomly assigned to standard…

This study tests whether adding an immune-boosting treatment (Sipuleucel-T) to ongoing hormone therapy can better control metastatic prostate cancer that has started to progress. About 26 men with asymptomatic or mildly symptomatic cancer will be randomly assigned to receive Sipu…

This study tests a drug called tarlatamab in people with a specific type of advanced prostate cancer (DLL3-positive) that has spread and either came back or didn't respond to prior treatments. About 32 participants will receive the drug to see if it can shrink tumors or slow the …

This study tests if adding a freezing procedure (cryoablation) and a chemotherapy drug (cyclophosphamide) to standard hormone therapy can better control metastatic prostate cancer. About 104 men with newly diagnosed, advanced prostate cancer will receive the combination treatment…

This study follows 170 men in China with metastatic prostate cancer who are receiving a radioactive drug called lutetium-177. Researchers will track how much PSA levels drop, how long the cancer stays controlled, and how patients feel during and up to a year after treatment. The …

This study tests a new drug called AZD0516, alone or with other cancer treatments, in people whose prostate cancer has spread to other parts of the body. The main goals are to check safety and find the best dose. About 177 adults with metastatic prostate cancer will take part. Th…

This study tests whether adding dexamethasone or metronidazole can make abiraterone work again for men with advanced prostate cancer that has stopped responding to treatment. About 58 men will receive one of these add-on drugs alongside their current therapy. The goal is to lower…

This early-stage trial tests a new drug called RO7656594 in people with advanced or metastatic prostate cancer. The goal is to check its safety, find the right dose, and see if it can help control the disease. About 210 participants will take part in this study.

This study is for men with advanced prostate cancer that no longer responds to hormone therapy and has certain DNA repair gene changes. It tests whether adding a platinum drug to the usual chemo (docetaxel) can delay cancer growth or spread. About 236 participants will be randoml…

This study tests a new treatment called AZD0754, which uses a patient's own immune cells (CAR T-cells) to fight metastatic prostate cancer. About 60 adults with castration-resistant prostate cancer will receive this therapy to see if it is safe and can shrink tumors or lower PSA …

This study tests whether a special PET scan using 18F-fluciclovine can better detect advanced prostate cancer that doesn't show up well on standard PSMA scans. About 30 people with metastatic prostate cancer that has low PSMA levels or neuroendocrine features will get the scan an…

This study tests whether a 16-week supervised exercise program (combining resistance, functional, and aerobic training) can improve frailty and muscle loss in 80 men with metastatic prostate cancer who are on hormone therapy. Participants must be pre-frail or frail. The goal is t…

This study looks at whether taking endocrine therapy in the morning or evening makes a difference for people with metastatic breast or prostate cancer. About 50 participants will be randomly assigned to take their medication at one of these times. The main goal is to see if a lar…

This study looks at whether two home-based exercise programs—using a stationary bike or walking—can help men with metastatic prostate cancer who are starting hormone therapy. Twenty-four participants will exercise at home for 12 weeks and complete fitness tests and questionnaires…

This study collects blood samples from 1000 men with prostate cancer to look for genetic differences that may explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. The goal is…

This study looks at ways to increase the number of men with metastatic prostate cancer who receive next-generation sequencing (NGS) testing. The researchers believe that by addressing obstacles for both doctors and patients, more men will get this important genetic test. About 25…

This study looks at whether having a radiopharmacist review a patient's full medication list before they receive targeted radionuclide therapy (TRT) can prevent drug-related problems. TRT uses radioactive drugs to kill cancer cells while sparing healthy tissue. The study will inc…